FDA Approves Ribociclib (Kisqali) for Stage 2-3 HR+/HER2- Breast Cancer at Higher Risk of Recurrence

FDA Approves Kisqali / Ribociclib for Early High-Risk Breast Cancer ESMO 2024Подробнее

Adding ribociclib to endocrine therapy shows an improvement in invasive DFS in HR+/HER2 BC patientsПодробнее

Frontline endocrine therapies and ribociclib in early stage HR+ HER2- breast cancerПодробнее

FDA Approved For Metastatic Breast CancerПодробнее

FDA Approval of Ribociclib for Metastatic Breast CancerПодробнее

Recent FDA Approval of Ribociclib as Upfront TherapyПодробнее

Dr. Kelly on the FDA Approval of Ribociclib in HR+ Breast CancerПодробнее

Kisqali (Ribociclib) for Breast Cancer: Uses, Side Effects, and What to ExpectПодробнее

Adjuvant CDK4 and 6 Inhibition to Prevent Recurrences in High-Risk HR+/HER2- Early Breast CancerПодробнее

New drug could lower chances of breast cancer returningПодробнее

HER2CLIMB FDA ApprovalПодробнее

Significance of the MONARCH 2 Findings for Abemaciclib in HR+/HER2- Breast CancerПодробнее

FDA Approval in HER2+ Breast Cancer, Priority Review in NSCLC, and MoreПодробнее

Raising the Bar in HR+/HER2- Early Breast Cancer: CDK4 and 6 InhibitorsПодробнее

A correlative analysis of CORALLEEN: preoperative ribociclib +letrozole vs chemo in HR+/HER2- BCПодробнее

ClarifyingComplexities of ExpandingTreatmentOptionsFor AdvancedAndEarly-Stage HR+/HER2- BreastCancerПодробнее

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Kaklamani and Dr. O’ReganПодробнее

HR–positive advanced breast cancer: Ribociclib improved PFS for pre and perimenopausal womenПодробнее

RIGHT Choice: ribociclib + ET vs combo chemo in aggressive HR+/HER2− advanced breast cancerПодробнее